Merus N.V. (MRUS) reports Q4 loss, revenue misses estimates, and future performance uncertain.

From Nasdaq: 2025-02-27 19:05:03

Merus N.V. (MRUS) reported a quarterly loss of $0.41 per share, beating the Zacks Consensus Estimate of a loss of $0.95. The company’s revenues of $9.14 million missed estimates by 22.35%. Merus shares have gained 8.3% this year. The company’s future stock performance will depend on earnings outlook and industry trends.

Investors are cautious about Merus N.V. (MRUS) as estimate revisions trend negative. The current Zacks Rank is #4 (Sell), indicating underperformance in the near future. Analysts expect a loss of -$1.08 per share for the next quarter and -$4.18 for the fiscal year. Industry rank for Medical – Biomedical and Genetics is promising.

Aprea Therapeutics, Inc. (APRE) is expected to report a quarterly loss of $0.68 per share, a 26.1% increase year-over-year. Revenues are expected to reach $0.45 million, up 4400% from last year. Investors can access free stock analysis reports from Zacks Investment Research for both Merus N.V. (MRUS) and Aprea Therapeutics, Inc.



Read more at Nasdaq: Merus N.V. (MRUS) Reports Q4 Loss, Lags Revenue Estimates